Metagenomi Therapeutics (MGX) Capital Expenditures (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Capital Expenditures of $124000.0 for Q1 2026, down 56.94% year-over-year from $288000.0 in Q1 2025, and up 45.88% quarter-over-quarter from $85000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Capital Expenditures (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Capital Expenditures for 4 consecutive years, with $124000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 56.94% year-over-year to $124000.0; the TTM figure through Mar 2026 stood at $410000.0 (down 86.26% YoY), while the FY2025 annual figure was $574000.0, down 81.57% from the prior year.
- Capital Expenditures advanced to $124000.0 in Q1 2026 per MGX's latest filing, from $85000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.4 million in Q2 2023 and bottomed at -$7.4 million in Q4 2023.
- Historically, Capital Expenditures has averaged $342307.7 across 4 years, with a median of $334000.0 in 2024.
- Annual changes were most pronounced in 2024 — Capital Expenditures jumped 104.49% — and 2025, when it tumbled 95.63%.
- Metagenomi Therapeutics' Capital Expenditures stood at -$7.4 million in 2023, then surged by 104.49% to $334000.0 in 2024, then plunged by 74.55% to $85000.0 in 2025, then surged by 45.88% to $124000.0 in 2026.
- Business Quant data shows MGX's Capital Expenditures at $124000.0 in Q1 2026, $85000.0 in Q4 2025, and $74000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 251.02 Mn |
| 10 | Metagenomi Therapeutics | 46.70 Mn | 46.70 Mn | - | 26,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26,000.00 |
| Jun 30, 2026 | 26,000.00 |
| Mar 31, 2026 | 124,000.00 |
| Mar 31, 2026 | 124,000.00 |
| Dec 31, 2025 | 85,000.00 |
| Dec 31, 2025 | 85,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 127,000.00 |
| Jun 30, 2025 | 127,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Sep 30, 2024 | 1.69 Mn |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 670,000.00 |
| Jun 30, 2024 | 670,000.00 |
| Mar 31, 2024 | 418,000.00 |
| Mar 31, 2024 | 418,000.00 |